Muscular Dystrophies and Neurologic Diseases that Present as Myopathy

Rheumatic Disease Clinics of North America

Volumn 37, Issue 2, 2011, Pages 233-244

  Quan, Dianna ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Muscle weakness; Muscular dystrophy; Myopathy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CORTICOSTEROID; LAMININ; LAMININ 111; UNCLASSIFIED DRUG;

BECKER MUSCULAR DYSTROPHY; BREATHING MUSCLE; CARDIOMYOPATHY; CLINICAL FEATURE; CONTRACTURE; DIET SUPPLEMENTATION; DISTAL MYOPATHY; DUCHENNE MUSCULAR DYSTROPHY; FASCIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENETIC SCREENING; HUMAN; JOINT HYPERMOBILITY; LIMB GIRDLE MUSCULAR DYSTROPHY; MIYOSHI MYOPATHY; MUSCLE HYPERTROPHY; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOPATHY; MYOTONIC DYSTROPHY; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WALKING AID;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; NERVOUS SYSTEM DISEASES; PHYSICAL EXAMINATION; POLYMYOSITIS;

EID: 79953030311     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2011.01.006     Document Type: Review

References (27)

1. Cohen N., Muntoni F. Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy. Heart 2004, 90:835-841.
2. Figarella-Branger D., Baeta Machado A.M., Putzu G.A., et al. Exertional rhabdomyolysis and exercise intolerance revealing dystrophinopathies. Acta Neuropathol 1997, 94:48-53.
3. Norwood F., de Visser M., Eymard B., et al. EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. Eur J Neurol 2007, 14:1305-1312.
4. Guglieri M., Straub V., Bushby K., et al. Limb-girdle muscular dystrophies. Curr Opin Neurol 2008, 21:576-584.
5. Sunada Y. Rinsho Shinkeigaku 2004, 44:995-997. [in Japanese].
6. Wheeler T.M., Thornton C.A. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007, 20:572-576.
7. Padberg G.W., van Engelen B.G. Facioscapulohumeral muscular dystrophy. Curr Opin Neurol 2009, 22:539-542.
8. Sewry C.A., Jimenez-Mallebrera C., Muntoni F. Congenital myopathies. Curr Opin Neurol 2008, 21:569-575.
9. Sharma M.C., Jain D., Sarkar C., et al. Congenital myopathies-a comprehensive update of recent advancements. Acta Neurol Scand 2009, 119:281-292.
10. Ravaglia S., Danesino C., Moglia A., et al. Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. Eur J Neurol 2010, 17(7):957-962.
11. Wokke J.H., Escolar D.M., Pestronk A., et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38:1236-1245.
12. Vielhaber S., Feistner H., Weis J., et al. Primary carnitine deficiency: adult onset lipid storage myopathy with a mild clinical course. J Clin Neurosci 2004, 11:919-924.
13. Maddison P., Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005, 2. CD003279.
14. Abu-Baker A., Rouleau G.A. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim Biophys Acta 2007, 1772:173-185.
15. Udd B., Bushby K., Nonaka I., et al. 104th European Neuromuscular Centre (ENMC) International Workshop: distal myopathies, 8-10th March 2002 in Naarden, The Netherlands. Neuromuscul Disord 2002, 12:897-904.
16. Sugie K., Yamamoto A., Murayama K., et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002, 58:1773-1778.
17. Aartsma-Rus A., van Ommen G.J. Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 2010, 18:146-153.
18. Wheeler T.M., Sobczak K., Lueck J.D., et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009, 325:336-339.
19. Miura P., Jasmin B.J. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?. Trends Mol Med 2006, 12:122-129.
20. Rooney J.E., Gurpur P.B., Burkin D.J. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2009, 106:7991-7996.
21. Tieleman A.A., den Broeder A.A., van de Logt A.E., et al. Strong association between myotonic dystrophy type 2 and autoimmune diseases. J Neurol Neurosurg Psychiatry 2009, 80:1293-1295.
22. Kissel J.T., Burrow K.L., Rammohan K.W., et al. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology 1991, 41:667-672.
23. Manzur A.Y., Kuntzer T., Pike M., et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, 1. CD003725.
24. Tidball J.G., Wehling-Henricks M. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol 2005, 17:707-713.
25. Groh W.J., Groh M.R., Saha C., et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008, 358:2688-2697.
26. Bourke S.C., Tomlinson M., Williams T.L., et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006, 5:140-147.
27. Dreher M., Rauter I., Storre J.H., et al. When should home mechanical ventilation be started in patients with different neuromuscular disorders?. Respirology 2007, 12:749-753.